European Regulatory Committee Recommends Approval of Celgene’s Revlimid and Imnovid-Based Triplet Combination Regimens for Patients with Multiple Myeloma

European Regulatory Committee Recommends Approval of Celgene’s Revlimid and Imnovid-Based Triplet Combination Regimens for Patients with Multiple Myeloma

Apr 5, 2019 | Committee for Medicinal Products for Human Use (CHMP), Multiple Myeloma, Positive Results

Celgene announced  the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene’s proprietary IMiD medications, Revlimid (lenalidomide) and Imnovid...

Pin It on Pinterest